secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-131739
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

4DMT appoints CFO Kristian Humer as Principal Accounting Officer
----------------------------------------------------------------

- Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.
- Humer continues as CFO and Principal Financial Officer (role since Nov 2025).
- Prior roles include CFO at Foghorn Therapeutics (Apr 2024–Nov 2025) and Viridian Therapeutics.
- Gupta remains Vice President, Finance and Controller of the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526131739/0001193125-26-131739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526131739/fdmt-20260325.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-131739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer